Excitement Builds for Skye Bioscience's Potential Weight Loss Game-Changer
Skye Bioscience's promising, safe weight loss drug, nimacimab, earned a "Buy" rating and $20 price target from analysts.
/ 935 items
#Healthcare↓
Adaptive: Why Analysts See It as a Dominant Force
Guggenheim rated ADPT a "Buy." It dominates blood cancer testing and will see major growth. "Shares are currently undervalued."
Major Buy Signal! Jefferies Initiates Coverage on Nuvation Bio
Jefferies issued a Buy rating on Nuvation Bio with a $10 price target, citing its FDA-approved lead drug, strong pipeline potential, and cash reserves extending into 2028.
AnaptysBio Plans to Split into Two Independent Companies
AnaptysBio announced plans to separate its business into 'Royalty Management Co' and 'Biopharma Co' by late 2026, aiming to unlock the potential value of its immunology pipeline and royalty assets.
FDA Scrutinizes Aurinia's Voclosporin Toxicity and Surrogate Endpoints
A top FDA official flagged the drug voclosporin as highly toxic, noting it was approved too quickly using ‘stand-in’ results (surrogate endpoints) without proving a direct benefit to patients. The FDA will now review this process to ensure approved drugs deliver real clinical results.
Oruka Therapeutics Stock Surges on Rival's Mixed Drug Trial Results
Oruka Therapeutics shares jump 30% as analysts predict gains following competitor MoonLake's Phase 3 results.